Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in ISG15-High Advanced NSCLC
NCT01607554Phase 2Terminated
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Apr 2012
- Primary completion
- Mar 2013
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in non-small cell lung cancer (NSCLC), sponsored by New Mexico Cancer Research Alliance. Primary endpoint: Tumor Response at 8 weeks. Started Apr 2012; status: terminated.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01607554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01607554.